WAYHELOVÁ, Markéta, Vladimíra VALLOVÁ, Eva HLADÍLKOVÁ, Hana FILKOVÁ, Jan OPPELT, Jana ŠOUKALOVÁ a Petr KUGLÍK. The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants. In ESHG 2020 - European Human Genetics Virtual Conference. 2020. ISSN 1018-4813.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants
Autoři WAYHELOVÁ, Markéta (203 Česká republika, domácí), Vladimíra VALLOVÁ (703 Slovensko), Eva HLADÍLKOVÁ (203 Česká republika, domácí), Hana FILKOVÁ (203 Česká republika, domácí), Jan OPPELT (203 Česká republika, domácí), Jana ŠOUKALOVÁ (203 Česká republika, domácí) a Petr KUGLÍK (203 Česká republika, garant, domácí).
Vydání ESHG 2020 - European Human Genetics Virtual Conference, 2020.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 10603 Genetics and heredity
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 4.246
Kód RIV RIV/00216224:14310/20:00116860
Organizační jednotka Přírodovědecká fakulta
ISSN 1018-4813
UT WoS 000598482603153
Klíčová slova anglicky neurodevelopmental disorders; NGS
Změnil Změnila: Mgr. Markéta Wayhelová, Ph.D., učo 357389. Změněno: 13. 5. 2021 17:48.
Anotace
Next-generation sequencing (NGS) techniques have become a powerful tool for the identification of the genetic causes of the heterogeneous conditions such as intellectual disabilities, multiple congenital anomalies and autism spectrum disorders. Here we present our first experience with targeted NGS approach using commercially available design SureSelect Inherited Disease (Agilent Technologies, Santa Clara, CA, USA) containing more than 2700 genes known to cause inherited disorders. We report on a case of 9-year-old boy with a diagnosis of severe intellectual disability related to early myoclonic encephalopathy. This patient was examined according to our investigatory algorithm, from G-banding karyotype (46,XY) to array-CGH on oligonucleotide DNA microarrays (Agilent Technologies, Santa Clara, CA, USA) followed by confirmative targeted quantitative PCR and FISH. We detected a de novo copy-number gain of 18q21.23 (539 kb), however, it could not explain his pathological phenotype. Consequently this patient was included in our pilot study using targeted NGS with pre-designed gene panel SureSelect Inherited disease and Illumina MiSeq. We detected de novo heterozygous missense genetic variant in SCN2A gene, resulting in the amino acid residue change from alanine to valine at position 263 (p.Ala263Val). This variant had been previously described as definitely pathogenic in patients with Otahara syndrome. This case has proved the usefulness and effectivity of our molecular diagnostics algorithm enhanced by NGS approaches leading to higher diagnostic yield of heterogeneous genetic conditions. This study was supported by IP 2016 (University Hospital, Brno) and the Specific Research Fund (Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno).
Návaznosti
MUNI/A/1127/2019, interní kód MUNázev: Podpora výzkumné činnosti studentů molekulární biologie a genetiky 8 (Akronym: MBG 8)
Investor: Masarykova univerzita, Podpora výzkumné činnosti studentů molekulární biologie a genetiky 8, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty
VytisknoutZobrazeno: 14. 5. 2024 04:09